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Phosphorylation of the pro-apoptotic protein BAD on serine 155,
a novel site, contributes to cell survival
K. Virdee*, P.A. Parone* and A.M. Tolkovsky
Phosphorylation of BAD, a pro-apoptotic member of the
Bcl-2 protein family, on either Ser112 or Ser136 is
thought to be necessary and sufficient for growth
factors to promote cell survival. Here we report that
Ser155, a site phosphorylated by protein kinase A
(PKA), also contributes to cell survival. Ser112 is
thought to be the critical PKA target, but we found that
BAD fusion proteins containing Ala at Ser112 (S112A)
or Ser136 (S136A) or at both positions (S112/136A)
were still heavily phosphorylated by PKA in an in vitro
kinase assay. BAD became insensitive to
phosphorylation by PKA only when both Ser112 and
Ser136, or all three serines (S112/136/155) were
mutated to alanine. In HEK293 cells, BAD fusion
proteins mutated at Ser155 were refractory to
phosphorylation induced by elevation of cyclic AMP
(cAMP) levels. Phosphorylation of the S112/136A
mutant was > 90% inhibited by H89, a PKA inhibitor. The
S155A mutant induced more apoptosis than the wild-
type protein in serum-maintained CHO-K1 cells, and
apoptosis induced by the S112/136A mutant was
potentiated by serum withdrawal. These data suggest
that Ser155 is a major site of phosphorylation by PKA
and serum-induced kinases. Like Ser112 and Ser136,
phosphorylation of Ser155 contributes to the
cancellation of the pro-apoptotic function of BAD.
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Results and discussion
Fusion proteins between glutathione-S-transferase and
BAD (GST–BAD) carrying the S112A or S136A muta-
tions, singly or in combination (S112/136A), were signifi-
cantly phosphorylated by PKA (Figure 1a). This effect
was evident for a range of PKA concentrations (0.5 and
0.1 units per reaction), ruling out the possibility that this
was an effect at a specific enzyme–substrate ratio. The
effect of PKA was abolished by the inclusion of the
inhibitor of PKA (PKI, 5 µM) in the in vitro kinase reac-
tion, indicating a specific requirement for PKA (Figure 1b).
These observations suggested that there was an, as yet,
unidentified site of PKA-dependent phosphorylation in
BAD. Our examination of the protein sequence of murine
BAD revealed that Ser155 is nested in a potential PKA
phosphorylation site (LRRMSDE in the single-letter
amino-acid code). To investigate whether this site was
responsible for the PKA-induced phosphorylation observed
in the S112/136A mutant, we generated GST–BAD fusion
Figure 1
Ser155 is the preferred site of phosphorylation by PKA. Bacterially
expressed GST–BAD fusion proteins eluted from glutathione–
sepharose beads were used as substrates in an in vitro kinase reaction
using either the purified catalytic subunit of PKA or constitutively active
PKB immunoprecipitated from PKB-expressing HeLa cells [20]. Kinase
reactions were conducted at 35°C for 30 min in the presence of a
reaction mix containing [γ-32P]ATP. The mixes were fractionated by
SDS–PAGE and the 32P-labelled GST–BAD proteins detected by
phosphorimaging. (a) PKA (1 unit per reaction) induces
phosphorylation of GST–BAD proteins containing the S112A and/or
S136A mutations but not proteins bearing the S155A mutation.
Protein expression was confirmed by western blotting with a polyclonal
anti-BAD antibody (H168, Santa Cruz). (b) Phosphorylation of wild-
type (WT) or S112/136A (DM) forms of GST–BAD by PKA is
independent of PKA concentration (in the range 1–0.1 units) and is
completely abolished by inclusion of PKI. (c) PKB phosphorylates only
those BAD proteins with an intact Ser136. The first lane shows that an
anti-PKB antibody immunoprecipitate from untransfected HeLa cells
binds GST–BAD (wild type). Results shown are representative of two
independent experiments.
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proteins bearing the S155A mutation. Confirming our pre-
diction, PKA failed to phosphorylate the S112/136/155A
mutant protein, even when PKA was added in excess.
Moreover, the S112/155A and S136/155A mutants were
largely refractory to PKA-induced phosphorylation, sug-
gesting that Ser155 is the preferred site of phosphorylation
by PKA (Figure 1a). We also confirmed reports that
Ser136 is the major site of phosphorylation by active
protein kinase B (PKB) [1–3], as none of our S136A mutants
were phosphorylatable in vitro by constitutively active
PKB (immunoprecipitated from HeLa cells overexpressing
PKB). Mutation of Ser112 or Ser155 had no effect on
PKB-mediated phosphorylation (Figure 1c). Thus, PKA
and PKB exhibit distinct preferences for Ser155 and
Ser136, respectively, of BAD.
To determine whether activation of PKA can induce phos-
phorylation of BAD at Ser155 in cells, we expressed fusion
proteins between various BAD mutants and the enhanced
green fluorescent protein (BAD–GFP) in HEK293 cells.
Following expression of the proteins (confirmed by probing
western blots with an anti-BAD antibody; Figure 2a, top
panel), the cells were metabolically labelled with 32P-
orthophosphate and treated with the cell-permeable
cAMP analogue 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic
monophosphate (CPTcAMP). BAD–GFP proteins were
then immunoprecipitated using anti-GFP antibody and
resolved by SDS–PAGE. CPTcAMP triggered the phos-
phorylation of wild-type BAD and the S112/136A mutant,
but not the S155A or S112/136/155A mutants (Figure 2a).
To further establish that PKA was responsible for the
observed phosphorylations, we examined the pattern of
phosphorylation after addition of the adenylyl cyclase
agonist forskolin (in the presence of the phosphodi-
esterase inhibitor IBMX) and added H89, the selective
inhibitor of PKA, to test whether phosphorylation could
be abolished. Figure 2b shows that treatment of HEK293
cells with 50 µM forskolin and 0.5 mM IBMX induced
phosphorylation of wild-type BAD and the S112/136A
mutant but not the S112/136/155A mutant. Moreover, pre-
incubation of cells with H89 (60 minutes, 30 µM) followed
by treatment with either CPTcAMP or forskolin and IBMX
resulted in a significant reduction (> 90%) in the phosphory-
lation of the S112/136A mutant (Figure 2b). Thus, in vivo
activation of PKA through elevation of intracellular cAMP
levels induces phosphorylation of BAD at Ser155.
To assess the functional importance of BAD phosphoryla-
tion on Ser155, we transfected CHO-K1 cells with plas-
mids encoding wild-type BAD, and the S112/136A,
S112/136/155A and S155A mutants, and measured the
extent of apoptosis (scored by nuclear morphology and
confirmed by polyADP ribose polymerase (PARP) cleav-
age). That mutation of these sites had no effect on the
expression of the respective protein was confirmed by
western blotting of lysates derived from transfected
CHO-K1 cells and probing with a monoclonal anti-BAD
antibody (Figure 3a). Figure 3b shows that, whereas the
expression of GFP alone did not promote apoptosis when
the cultures were maintained in serum-containing medium,
the absence of Ser155 was sufficient to exacerbate the
pro-apoptotic function of wild-type BAD. The amount of
apoptosis induced by the S112/136/155A mutant was
invariably greater than that induced by either the S155A
or S112/136A mutants. In the absence of serum, the level
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Figure 2
Elevation of intracellular cAMP levels in HEK293 cells causes
phosphorylation of wild-type BAD and the S112/136A mutant but not
the S112/136/155A or S155A mutants. (a) BAD proteins lacking
Ser155 are refractory to phosphorylation in cells. HEK293 cells were
transfected with plasmids encoding the indicated BAD–GFP proteins
and starved of serum (15 h) before labelling with 32P-labelled
orthophosphate (1 mCi/ml) for 6 h. For the last 30 min of this labelling
period, the cells were stimulated with CPTcAMP (500 µM). The
expressed proteins (confirmed by western blotting with anti-BAD
antibody, top panel) were immunoprecipitated with anti-GFP antibody
(Clontech), separated by SDS–PAGE, and the 32P-labelled BAD–GFP
proteins were detected by phosphorimaging. (b) Transfected HEK293
cells were labelled with 32P-orthophosphate and stimulated with either
CPTcAMP (500 µM) or 50 µM forskolin and 0.5 mM IBMX for the last
30 min. Cells expressing the S112/136A mutant (with intact Ser155)
were pretreated with H89 (60 min, 30 µM) before stimulation with
CPTcAMP or forskolin and IBMX. As a control, untransfected cultures
were also treated with forskolin and IBMX, and subjected to the
immunoprecipitation procedure as described above. H89 reduced
phosphorylation of the S112/136A mutant by > 90%.
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of apoptosis observed in cells expressing wild-type BAD,
or the S155A or S112/136A mutants was enhanced com-
pared with that observed in the presence of serum for the
respective protein, but there was no significant increase in
apoptosis of cells expressing the triply mutated protein.
Although these data confirm the existence of serum
factor(s) that induce the phosphorylation of Ser112 and/or
Ser136, the data also reveal the importance of Ser155 as a
regulatory site for the pro-apoptotic activity of BAD.
These results do not, however, exclude the possibility that
serum-activated kinases other than PKA might be respon-
sible for the observed effects. In the presence of the pan-
caspase inhibitor Boc.Asp(O-methyl)CH2F (BAF), apoptosis
induced by the triple mutant was completely suppressed
(data not shown). Likewise, the extent of cleavage of
PARP was greater in cells expressing BAD proteins bearing
the S155A mutation and this cleavage was substantially
blocked by BAF (Figure 3c). Similar data were obtained
using HeLa cells (data not shown). Thus, Ser155 can regu-
late the pro-apoptotic effect of BAD in live cells.
BAD is a pro-apoptotic member of the Bcl-2 family of pro-
teins that exerts its death-promoting activity by het-
erodimerising with Bcl-XL or Bcl-2, death antagonists
located mainly in the mitochondria [4]. In response to
stimulation by survival factors, BAD has been shown to be
phosphorylated on Ser112 (RSRHSpSYP) and Ser136
(RQRSTpSTP), upon which it dissociates from Bcl-
XL/Bcl-2 and becomes sequestered by 14-3-3 proteins in
the cytosol [5]. Although both serines lie within PKB con-
sensus sequences (RXRXXS), only Ser136 appears to be
phosphorylated by PKB [1–3]. Phosphorylation of Ser112
is mediated by PKA [6], or by pp90RSK through a
pathway dependent on the kinase MEK [7–9]. The
p21-activated kinase 1 (PAK1) also phosphorylates BAD
in vitro and in vivo on both Ser112 and Ser136 and inhibits
the pro-apoptotic effects of BAD [10]. The existence of
other sites in BAD that are phosphorylated by other
kinases has also been suggested recently; for example,
granulocyte macrophage colony stimulating factor
(GMCSF) stimulates both cell survival and phosphoryla-
tion of BAD in the absence of detectable PKB activity
[11,12]. Moreover, Raf-1 targeted to mitochondria also
phosphorylates BAD at sites other than Ser112 and Ser136
[13–15]. However, the methods used to reveal BAD phos-
phorylation in these studies preclude identification of the
specific residue(s) involved. We have now found that
Ser155 is an important PKA-dependent phosphorylation
site in BAD. The general role of BAD phosphorylation in
the maintenance of cell survival is still controversial and,
moreover, the mechanism by which BAD is phosphory-
lated is more complicated than was previously thought.
The identification of Ser155 as a site in BAD that is phos-
phorylated in vivo provides another mechanism by which
BAD can integrate signals from upstream kinases.
Although both Ser112 and Ser136 are nested within con-
sensus binding motifs for 14-3-3 [16,17], the flanking
sequences around Ser155 do not conform to a 14-3-3-
binding motif. Ser155 of murine BAD is, however, located
within the BH3 domain that has previously been shown to
be crucial for the interaction of BAD with other Bcl-2
family members [18]. Thus, it is likely that phosphorylation
of Ser155 is sufficient to induce a conformational change
that enhances the dissociation of BAD from Bcl-2/Bcl-XL.
In summary, we have identified Ser155 as the major PKA-
and serum-dependent phosphorylation site in BAD, and
shown that its mutation enhances the pro-apoptotic func-
tion of BAD in living cells.
Materials and methods
Tissue culture, transfections and measurement of apoptosis
CHO-K1 cells were maintained in Ham F-12 medium (Gibco) contain-
ing 10% heat-inactivated fetal bovine serum. HEK293 cells were main-
tained in DMEM containing 10% fetal calf serum. For transfections,
cells were grown overnight in 24-well plates washed three times in
Optimem 1 (Gibco) and transfected with 0.1 pmol of the BAD–GFP
expression vectors using 3 µl Lipofectamine (Gibco) per well. After 4 h,
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Figure 3
Substitution of Ser155 by Ala results in a
gain of apoptotic function. (a) CHO-K1
cells were transfected with the indicated
BAD constructs and, after 15 h, lysates
were resolved by SDS–PAGE, blotted onto
nitrocellulose and analysed for BAD–GFP
expression using a monoclonal anti-BAD
antibody. (b) CHO-K1 cells transfected as
in (a) were incubated for 18 h in medium
containing 10% serum, after which the cells
were transferred either to serum-free
medium or maintained in serum-containing
medium for an additional 12 h. After this
time, the green cells (transfectants) were
scored for apoptosis by Hoechst staining.
The bars show mean and range for
duplicate wells. (c) CHO-K1 cells were
transfected with constructs expressing the
indicated proteins and incubated for 15 h in
the absence or presence of BAF, after
which whole cell lysates were resolved
and blotted as above and analysed for
PARP cleavage (∆PARP). The results
shown are representative of two
independent experiments.
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the cultures were switched to serum-containing medium for 15–18 h
before exposure to the treatments indicated in the figure legends.
BAD–GFP fusion proteins were detected on western blots using a
polyclonal anti-BAD antibody, H168 (Santa Cruz). To determine the
amount of apoptosis, cells were stained with Hoechst 33342
(2.5 µg/ml; Sigma) and the fraction of green cells (transfectants) dis-
playing fragmented nuclei was calculated. PARP cleavage was mea-
sured using a monoclonal antibody as described [19].
Plasmid and DNA construction
To generate GST fusion constructs of wild-type BAD, and the S112A,
S136A and S112/136A mutants, full-length murine bad cDNA
sequences were amplified from the respective pSSFVBad recombinant
vectors (kindly provided by Stanley Korsmeyer) by PCR and ligated into
the pGEX4T-1 expression vector (Pharmacia) in frame with the car-
boxyl terminus of the GST coding sequence. The S155A mutants were
generated by PCR site-directed mutagenesis (Quickchange, Strata-
gene) using the respective pGEX-Bad constructs as templates. GST
fusion proteins were expressed in Escherichia coli strain BL21 and
purified on glutathione–Sepharose beads (Pharmacia). To generate
BAD–GFP fusion constructs, full-length sequences of murine Bad
were subcloned from the respective pSSFVmBad recombinant vectors
into the pEGFP-N1 mammalian expression vector (Clontech). The
S155A constructs were generated by PCR site-directed mutagenesis
using the respective pEGFP–mBad constructs as templates.
In vitro kinase assays
To measure BAD phosphorylation, respective GST–BAD fusion pro-
teins (10–20 µg) were added to buffer containing 50 mM Tris-Cl
(pH 7.4), 10 mM MgCl2, 1 mM DTT, 10 mM β-glycerophosphate,
50 µM ATP and 20 µCi [γ-32P]ATP (Amersham). For PKA assays,
0.5 units of the catalytic subunit of PKA (P2645, Sigma) was added
per reaction. In some cases, PKI (Bachem) was also added (5 µM). For
PKB activity assays, a construct encoding the membrane-targeted form
of PKB [20] was transfected into HeLa cells using Lipofectamine; 36 h
post transfection, active PKB was immunoprecipitated from the deter-
gent solubilised lysates using a polyclonal PKB antibody (a gift from
Brian Hemmings) as described in [20]. Kinase reactions were con-
ducted at 35°C for 30 min and terminated by the addition of
SDS–PAGE loading buffer. The proteins were resolved on a
SDS–polyacrylamide gel (7.5 or 10%) and 32P-labelled fusion proteins
were detected using a phosphorimager (Molecular Dynamics).
Metabolic labelling
HEK293 cells were transfected in 35 mm dishes as described above,
washed once in serum- and phosphate-free RPMI and then incubated in
phosphate-free RPMI (Gibco) buffered with sodium bicarbonate
(2.2 g/l) containing 1 mCi 32P-labelled orthophosphate (Amersham) for
6 h in a humidified atmosphere of 5% CO2/95% air. BAD–GFP was
immunoprecipitated from detergent-solubilised lysates with an anti-GFP
antibody (Clontech) and the immune complexes captured using protein
A/G agarose. After washing in high salt (0.5 M NaCl) lysis buffer, the
immunoprecipitates were eluted by boiling in gel loading buffer and frac-
tionated on an SDS–polyacrylamide gel (10%); 32P-labelled BAD–GFP
was detected using a phosphorimager (Molecular Dynamics).
Supplementary material
Supplementary material including images of transfected cells is avail-
able at http://current-biology.com/supmat/supmatin.htm.
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